ARN-509 is an androgen receptor signaling inhibitor currently in phase 2 clinical trial for castration-resistant prostate cancer (CRPC). How does ARN-509 work to block prostate cancer cells is described below.
Oncology targets, strategies, cancer drug development and personalized medicine
Showing posts with label arn509. Show all posts
Showing posts with label arn509. Show all posts
Tuesday, September 24, 2013
Saturday, October 30, 2010
The Prostate Cancer: New drugs in the post “Abiraterone-Jevtana-Provenge” world
The success of three new drugs (Abiraterone, Jevtana and Provenge) for castration-resistant prostate cancer (CRPC) this year, each targeting different pathways, and all showing an overall survival benefit, has raised the bar for those dreaming to join the club. There is at least one riding the popularity vote, MDV3100, which may complete phase 3 next year. Still, many struggle and plough through phase 1 and 2. One way to understand, what may make some of them unique – and the reason they may evolve into serious competition one day – is to lay them out in separate classes or targets. This is what I have done below.
Subscribe to:
Posts (Atom)